(Q50927518)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Guidelines for treatment of atopic eczema (atopic dermatitis) part I (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Jacek Szepietowski

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

J Ring

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Alomar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

T Bieber

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M Deleuran

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Fink-Wagner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

C Gelmetti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

U Gieler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Lipozencic

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

T Luger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A P Oranje

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

T Schäfer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

T Schwennesen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

S Seidenari

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

D Simon

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

G Stingl

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

S Szalai

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Taïeb

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

T Werfel

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Wollenberg

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

U Darsow

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

European Dermatology Forum (EDF)

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

European Academy of Dermatology and Venereology (EADV)

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

European Federation of Allergy (EFA)

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

European Task Force on Atopic Dermatitis (ETFAD)

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

European Society of Pediatric Dermatology (ESPD)

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Global Allergy and Asthma European Network (GA2LEN)

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

Journal of the European Academy of Dermatology and Venereology

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

1045-1060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Factors associated with the development of peanut allergy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Oat sensitization in children with atopic dermatitis: prevalence, risks and associated factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Viral infections in atopic dermatitis Pathogenic aspects and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Influence of short-term exposure to airborne Der p 1 and volatile organic compounds on skin barrier function and dermal blood flow in patients with atopic eczema and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Airway diseases and allergies in East and West German children during the first 5 years after reunification: time trends and the impact of sulphur dioxide and total suspended particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The effect of environmental tobacco smoke on eczema and allergic sensitization in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Domestic allergens and endotoxin in three hospitals offering in-patient rehabilitation for allergic diseases in the alpine mountain climate of Bavaria - The AURA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Late eczematous reactions to food in children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

EAACI/GA2LEN position paper: present status of the atopy patch test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Wheat allergy: diagnostic accuracy of skin prick and patch tests and specific IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The role of the atopy patch test (APT) in diagnosis of food allergy in infants and children with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Combined skin prick and patch testing enhances identification of peanut-allergic patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The atopy patch test in the diagnostic workup of suspected food-related symptoms in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Standardization of double-blind, placebo-controlled food challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Dietary exclusions for improving established atopic eczema in adults and children: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic DermatitisStudy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The use of corticosteroids and corticosteroid phobia in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Atopic dermatitis and asthma: parallels in the evolution of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Evidence-based (S3) guideline on topical corticosteroids in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Glucocorticoids inhibit double-stranded RNA-induced thymic stromal lymphopoietin release from keratinocytes in an atopic cytokine milieu more effectively than tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Macrolactam immunomodulators for topical treatment of inflammatory skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The role of topical calcineurin inhibitors in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Practice experience with topical calcineurin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Heal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Topical tiacrilast, a potent mast cell degranulation inhibitor, does not improve adult atopic eczema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

A pilot study examining the role of zileuton in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

21 January 2018

Opiates, sleep and itch.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Treatment of itching in atopic eczema with antihistamines with a low sedative profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Safety of levocetirizine treatment in young atopic children: An 18-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Atopic dermatitis: a disease caused by innate immune defects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Innate immunity, allergy and atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Isolation of alpha-toxin-producing Staphylococcus aureus from the skin of highly sensitized adult patients with severe atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The case for steroid--antibiotic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Bacterial infection and atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Flucloxacillin in the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Efficacy and functionality of silver-coated textiles in patients with atopic eczema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Secondary infections in patients with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

The role of Malassezia in atopic dermatitis affecting the head and neck of adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04635.X

10.1111/J.1468-3083.2012.04635.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22805051%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference